Navigation Links
The complete map of the Germany E. coli O104 genome released
Date:6/16/2011

Building upon previous efforts producing a high-quality de novo genome assemblies of deadly 2011 E. coli O104:H4 outbreak strain (http://www.genomics.cn/en/news_show.php?type=show&id=651), the BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released the first complete map of the genome and plasmids without any assembly gaps. (genome publicly available at ftp://ftp.genomics.org.cn/pub/Ecoli_TY-2482/Escherichia_coli_TY-2482.chromosome.20110616.fa.gz and plasmids at ftp://ftp.genomics.org.cn/pub/Ecoli_TY-2482/Escherichia_coli_TY-2482.plasmid.20110616.fa.gz)

BThis final draft of the genome shows the disease strain has a circular chromosome 5,278 kbp in length, and three additional plasmids 88 kbp, 75 kbp and 1.5 kbp in size, respectively. The chromosome contains around 5,000 predicted coding sequences (CDSs), covering 87.09% of the genome. The biggest plasmid is highly homologous to a previously sequenced plasmid isolated from a horse and carrying additional multi-drug resistance genes; the smallest one is a so-called "selfish plasmid" carrying only two genes, one of which encodes a DNA replication protein; the other carrying the aggregative adherence fimbria I (AAF/I) gene cluster, which is associated with E. coli aggregation ability and virulence, and likely to play a role in the persistence of the disease.

BGI researchers found that the Shiga-toxin-encoding genes, responsible for most of the pathogenicity of the disease, were likely encoded by a viral prophage that integrated in the bacterial chromosome. Several insertion hotspots, including one nested multi-antibiotic resistant associated locus, were also identified in the research. This indicates that horizontal gene transfer events may have played important roles in the evolution of virulence and drug resistance of this strain.

The results of these and previous phylogenetic and comparative genomic analyses now give us the confidence to confirm that the outbreak strain belong to an EAEC (enteroaggregative E. coli) lineage, but acquired the Shiga toxin producing ability by the integration of a phage genome. This explains the initial confusion as to why the EAEC-lineage bacteria harbored some characteristics of EHEC (enterohaemorrhagic E. coli) strains. Therefore, the deadly Germany E. coli is not a completely new bacteria and can be considered a "hybrid" strain, now temporarily termed Shiga toxin-producing enteroaggregative Escherichia coli (STpEAEC).

BGI has a new portal collecting most of the genomic evidence, and due to the urgency in fighting the outbreak, BGI's data has been released under a public domain license. To aid the growing crowdsourcing effort this is accessible for the first time via a data DOI a digital object identifier that allows citation of a dataset before formal publication. These novel ways of freely and publicly releasing of information has allowed unprecedentedly rapid progress in understanding the genomic insights of this infection, and a growing team of researchers have now confirmed they will also release their work in the same manner (see: http://bacpathgenomics.wordpress.com/2011/06/13/e-coli-data-released-under-creative-commons-0-license/). Please see the Github repository for the latest open research by the E. coli community and our portal page:


'/>"/>

Contact: Bicheng Yang
yangbicheng@genomics.cn
86-150-138-65386
Beijing Genomics Institute
Source:Eurekalert

Related biology news :

1. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
2. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
3. DOE Joint Genome Institute completes soybean genome
4. Sequencing of sorghum genome completed
5. Complete Genomics releases proof-of-concept data for its sequencing technology for the first time
6. Animals that seem identical may be completely different species
7. Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products
8. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
9. A complete view of complexity in science and society in a new authoritative reference work
10. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
11. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
(Date:2/23/2017)... Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a ... conditions, today announced that Linda Marbán, Ph.D, president and chief ... conferences: Cowen and Company 37th Annual ... ET Boston, MA ... am PT (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... ANGELES, CA (PRWEB) , ... February 22, 2017 ... ... today announced that is has acquired Kendall Research Systems, LLC (KRS) ... Technology (MIT) that develops neural interface technology for research and clinical applications. The ...
Breaking Biology Technology: